구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | High Dose Chemotherapy |
Overview Company | Celgene |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | vedotin (BV) maintenance therapy improves patie |
MoA Mechanism | targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen |
MoA Biomarker | biomarkers are critical to predict which patients will require treatment escalation |
PK/PD Half-life | 47 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.. Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of… |
Clinical Safety signal | Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.. Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of… |
Clinical Selected reported efficacy | ORR 29% |
Clinical Reported ORR | 29% |
Clinical Result source | ClinicalTrials.gov NCT01182415 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT01182415 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | High Dose Chemotherapy |
Overview Company | Celgene |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | vedotin (BV) maintenance therapy improves patie |
MoA Mechanism | targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen |
MoA Biomarker | biomarkers are critical to predict which patients will require treatment escalation |
PK/PD Half-life | 47 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.. Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of… |
Clinical Safety signal | Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.. Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of… |
Clinical Selected reported efficacy | ORR 29% |
Clinical Reported ORR | 29% |
Clinical Result source | ClinicalTrials.gov NCT01182415 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT01182415 |
추천 비교
추천 비교